{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:53:19Z","timestamp":1777578799084,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.006","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T08:01:47Z","timestamp":1596614507000},"page":"887-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Minimal Residual Disease in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Marco","family":"Ladetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Tavarozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.hoc.2020.06.006_bib1","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.006_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1752.1752","article-title":"The addition of rituximab to CHOP improves failure-free and overall survival of mantle-cell lymphoma patients\u2014a pooled trials analysis of the German Low-Grade Lymphoma Study Group (GLSG) [abstract]","volume":"124","author":"Hoster","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.006_bib3","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.006_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/blood.V116.21.110.110","volume":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.006_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Nordic Lymphoma Group. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.006_bib6","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.006_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.006_bib8","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Beldi-Ferchiou A, Cacheux V, et\u00a0al. Obinutuzumab plus DHAP followed by ASCT plus Obinutuzumab maintenance provides a high MRD response rate in untreated patients with MCL, results of the LYMA-101 trial, a LYSA group study. Abstract S103. 24th European Hematology Association Congress, Amsterdam, NL, June 14, 2019.","DOI":"10.1097\/01.HS9.0000558632.47592.16"},{"key":"10.1016\/j.hoc.2020.06.006_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.006_bib10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"German Low-Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.006_bib11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.006_bib12","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.006_bib13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2020.06.006_bib14","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.006_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: Insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.006_bib16","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"Dongen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.006_bib18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmoldx.2015.05.007","article-title":"Minimal residual disease detection by droplet digital PCR in multiple myeloma , mantle cell lymphoma , and follicular lymphoma a comparison with real-time PCR","volume":"17","author":"Drandi","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.hoc.2020.06.006_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-62703-269-8_10","article-title":"MRD detection in B-cell non-hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR","volume":"971","author":"Pott","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.hoc.2020.06.006_bib20","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study","volume":"33","author":"Br\u00fcggemann","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.006_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: An EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.006_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/hon.989","article-title":"Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms","volume":"29","author":"Ferrero","year":"2011","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.006_bib23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"B\u00f6ttcher","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.006_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cytob.21210","article-title":"Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach","volume":"88","author":"Chovancov\u00e1","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.006_bib25","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.006_bib26","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.006_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cyto.a.22581","article-title":"Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds","volume":"87","author":"Kalina","year":"2015","journal-title":"Cytometry A"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.006_bib29","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.006_bib30","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","article-title":"Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2020.06.006_bib31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood.V126.23.696.696","article-title":"Targeted locus amplification & next generation sequencing for the detection of recurrent and novel gene fusions for improved treatment decisions in pediatric acute lymphoblastic leukemia","volume":"126","author":"Kuiper","year":"2015","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2020.06.006_bib32","first-page":"2742","article-title":"Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma. Abstract","volume":"30","author":"Genuardi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-114442","article-title":"Comprehensive Minimal Residual Disease (MRD) analysis of the fondazione italiana linfomi (FIL) MCL0208 clinical trial for younger patients with mantle cell lymphoma: a kinetic model ensures a more refined risk stratification","volume":"132","author":"Ferrero","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.006_bib34","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biology of blood and marrow transplantation","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.006_bib35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0301-472X(02)00807-X","article-title":"Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1\/JH rearrangements in mantle cell lymphoma","volume":"30","author":"Andersen","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.hoc.2020.06.006_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0301-472X(00)00651-2","article-title":"A\u00a0validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex\u00a0vivo purging in follicular lymphoma patients","volume":"29","author":"Ladetto","year":"2001","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.006_bib37","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.leu.2401831","article-title":"Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR","volume":"14","author":"Bruggemann","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.006_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.06.006_bib39","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib40","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib41","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","article-title":"on behalf of the EuroClonality-NGS Working Group. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.006_bib42","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a non-randomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma\u00a0> 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.006_bib44","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.006_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.147.147","article-title":"MRD eradication should be the therapeutic goal in mantle cell lymphoma and may enable tailored treatment approaches: results of the intergroup trials of the European MCL Network [abstract]","volume":"124","author":"Pott","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.006_bib46","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.006_bib47","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.006_bib48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2017.167627","article-title":"Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?","volume":"102","author":"Ferrero","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.006_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.338.338","article-title":"Predictive Power of Early, Sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; interim results from the LyMa-MRD Project","volume":"126","author":"Callanan","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.006_bib50","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.006_bib51","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term Remission in Mantle Cell Lymphoma Following High-Dose Sequential Chemotherapy and in Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.006_bib52","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in\u00a0vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib53","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.006_bib54","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V116.21.965.965","article-title":"R-CHOP\/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network","volume":"116","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"suppl 4","key":"10.1016\/j.hoc.2020.06.006_bib55","article-title":"R-CHOP vs R-FC followed by maintenance with rituximab or IFN: First results of MRD assessment within the randomized trial for elderly patients with MCL [abstract]","volume":"22","author":"Pott","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.006_bib56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A\u00a0phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.006_bib57","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V124.21.148.148","article-title":"Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial by the Lysa Group","volume":"124","author":"Gressin","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.006_bib58","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2020.06.006_bib59","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJM199111283252201","article-title":"Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma","volume":"325","author":"Gribben","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.006_bib60","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.006_bib61","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Nordic Lymphoma Group. Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; Results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2020.06.006_bib62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3324\/haematol.2018.191429","article-title":"A\u00a0phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma","volume":"104","author":"Gressin","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.006_bib63","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood-2018-99-112655","article-title":"Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8 year follow up of CALGB 50403 (alliance)","volume":"132","author":"Kaplan","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.006_bib64","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hon.2550","article-title":"R\u00a0Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance","volume":"36","author":"Klener","year":"2018","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.006_bib65","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00277-013-1797-y","article-title":"Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma","volume":"92","author":"Ferrero","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2020.06.006_bib66","doi-asserted-by":"crossref","unstructured":"Federico M, Mannina D, Versari A, et\u00a0al. Response oriented maintenance therapy in advanced follicular lymphoma. Results of the interim analysis of the FOLL12 TRIAL conducted by the Fondazione Italiana Linfomi. Abstract (2019). https:\/\/doi.org\/10.1002\/hon.110_2629.","DOI":"10.1002\/hon.110_2629"},{"issue":"15 suppl","key":"10.1016\/j.hoc.2020.06.006_bib67","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1200\/JCO.2017.35.15_suppl.7558","article-title":"Allogeneic hematopoietic stem cell transplantation for mantle cell lymphoma in a heavily pretreated patient population","volume":"35","author":"Kobrinski","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.006_bib68","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood.V120.21.3092.3092","article-title":"Autologous and allogeneic donor transplantation for mantle cell lymphoma in rituximab era: impact of pre-transplant burden on survival. clinical allogenic and autologous transplantation \u2013poster II","volume":"120","author":"Magnusson","year":"2012","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:13:38Z","timestamp":1760184818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300691"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal Residual Disease in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}